Form D · Biotechnology
Insitro, Inc.
South San Francisco, CA · CIK 0001812648
Offering snapshot reported May 27, 2020 · SEC filing
- Reported sold
- $143M Offering amount: $143M
- Investors reported
- 26 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 26, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 27, 2020 | Initial | $143,210,951 | No comparison | 26 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-367759
Source: Form D, filed May 27, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Daphne Koller | Director, Executive |
| Robert Nelsen | Director |
| Vijay Pande | Director |
| Mary Rozenman | Executive |
| Duane Valz | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
279 East Grand Avenue, Suite 200
South San Francisco, CA, 94080
South San Francisco, CA, 94080